Eli Lilly said Monday that a high dose of its gene-editing therapy reduced cholesterol levels by 62% in participants in a clinical trial.

Jeffery Taubenberger, the acting head of the NIAID, the NIH’s infectious disease institute, is reported to have stepped down.

In response to an Ebola outbreak, the U.S. has banned entry for noncitizens who have been in the Democratic Republic of the ...

After a quick break, I’ll bring you our conversation about perimenopause, menopause, and what happens when women are seen as ...

Amid another Ebola outbreak, hundreds of Africans are sick, displaced, fearful, or dead. Health care workers across Central ...

President Trump's cuts to foreign aid probably hampered the detection of the Ebola outbreak and the response to it.

My patients are replacing olive oil with beef tallow, even if they don't tell me during cardiac rehab,” writes a clinical ...

With no approved vaccine for the fast-growing Ebola outbreak in the DRC, experts weigh testing one with unknown protection.

Biogen and Denali Therapeutics said a closely watched experimental therapy for Parkinson’s disease failed to slow the ...

Merck-Kelun ADC outperforms Keytruda in trial, a closely watched Parkinson’s drug fails, and more biotech news from The ...

A public health advisory calls on parents, schools, and government to limit children's use of screens, saying some patterns ...

Far fewer knew that mpox and Zika can also be transmitted sexually. And most respondents understood the main ways that these ...